PsymaTalk: Our Take on ASCO 2018 - Part 2

with Gordon Gochenauer, Oncology lead at Psyma USA

Gordon Gochenauer, shares his takeaways from ASCO 2018 in a podcast miniseries. (Episode 2)

In this 2nd episode of our post ASCO 2018 miniseries, Gordon Gochenauer shares his takeaways on breast cancer trial results.  Novartis’ CDK4/6 inhibitor, Kisqali, rounds out its clinical portfolio with the MONALEESA-3 trial in a further attempt to unseat Pfizer’s Ibrance and differentiate itself from Eli Lilly’s Verzenio.  Also, AKT inhibitors, ipatasertib from Genentech and capavasertib from AstraZeneca, provide further evidence that PIK3CA/AKT/PTEN-alterations can be another precision medicine target for breast cancer.

 

Contact us to find out more about our Oncology Practice.

 

Psyma Group AG

Rueckersdorf/Nuremberg Germany
Phone: +49 (0)911 99574-0
E-Mail: info@psyma.com